What is the recommended diagnostic work‑up and treatment for restrictive cardiomyopathy?

Restrictive Cardiomyopathy: Diagnostic Work-Up and Treatment

Begin diagnostic evaluation with echocardiography to assess for restrictive physiology (rapid early diastolic filling, biatrial enlargement, non-dilated ventricles with preserved or reduced ejection fraction), followed immediately by screening for cardiac amyloidosis with serum/urine immunofixation electrophoresis and serum free light chains, as this is the most common treatable cause of restrictive cardiomyopathy. 1

Diagnostic Algorithm

Initial Evaluation - Red Flag Clinical Features

Look specifically for these clinical patterns that distinguish different etiologies:

• Cardiac amyloidosis: Discordance between increased LV wall thickness (≥14 mm) and low QRS voltage on ECG, fatigue, dyspnea, carpal tunnel syndrome, spinal stenosis, autonomic/sensory polyneuropathy 1
• Cardiac sarcoidosis: Abnormal ECG with conduction abnormalities, >100 ventricular ectopic beats per 24 hours on Holter monitoring 2
• Iron overload: History of transfusion-dependent anemia or hereditary hemochromatosis 3

Step-by-Step Diagnostic Pathway

Step 1: Echocardiography 4, 5

• Assess for biatrial enlargement, non-dilated ventricles, restrictive filling pattern
• Evaluate for apical sparing pattern of longitudinal strain (suggests amyloidosis)
• Measure wall thickness and assess systolic function

Step 2: Immediate Amyloidosis Screening 1 Order simultaneously:

• Serum immunofixation electrophoresis (IFE)
• Urine immunofixation electrophoresis
• Serum free light chains
• This combination is >99% sensitive for AL amyloidosis

Step 3: If Monoclonal Light Chains Are Negative 1

• Perform technetium-99m pyrophosphate (99mTc-PYP) bone scintigraphy
• Grade 2/3 cardiac uptake or heart-to-contralateral (H/CL) ratio >1.5 confirms ATTR cardiac amyloidosis with very high specificity
• Critical pitfall: Never interpret bone scan without first ruling out light chain disease, as AL amyloidosis can also show positive uptake

Step 4: If ATTR Confirmed 1

• Perform TTR gene sequencing to differentiate hereditary variant (ATTRv) from wild-type (ATTRwt)
• This distinction is essential as it affects family screening and treatment approach

Step 5: Cardiac MRI with Late Gadolinium Enhancement 6 If amyloidosis excluded or for further characterization:

• Amyloidosis pattern: Global subendocardial or diffuse LGE with abnormal gadolinium kinetics
• Sarcoidosis pattern: Patchy mid-myocardial LGE, preferentially basal septum and lateral walls 2
• Iron overload: Reduced T2* signal

Step 6: For Suspected Sarcoidosis 2

• Cardiac MRI or PET with fluorodeoxyglucose imaging (Level of Evidence B)
• Holter monitoring for ventricular arrhythmias
• Endomyocardial biopsy can confirm with noncaseating granulomas, but negative biopsy does not exclude diagnosis (patchy distribution, only 25-50% sensitivity) 2

Step 7: Cardiac Catheterization 4, 5 When diagnosis remains uncertain or to differentiate from constrictive pericarditis:

• Demonstrates rapid early diastolic pressure rise with plateau ("square root sign")
• LV end-diastolic pressure typically ≥20 mmHg
• Concordant respiratory variation in LV/RV pressures (systolic area index ~1.0) supports RCM over constriction

Step 8: Genetic Testing 5, 7 Consider next-generation sequencing for:

• Troponin I (TNNI3) mutations
• Other sarcomeric gene variants
• Particularly important in pediatric cases or when family history present

Treatment Approach

Disease-Specific Therapies (Priority Order)

1. ATTR Cardiac Amyloidosis 8, 3

• Tafamidis (transthyretin stabilizer): First-line disease-modifying therapy with demonstrated improved cardiac function and survival
• Emerging therapies in clinical trials: antisense oligonucleotides, RNA interference therapies, gene-editing strategies 8

2. Cardiac Sarcoidosis 2

• Corticosteroids are the mainstay (Level of Evidence B): Start prednisone 40-60 mg daily, taper slowly over months if stable/improved
• Monitor closely for relapse after discontinuation
• Alternative immunosuppressives if corticosteroid intolerance or inadequate response: methotrexate, azathioprine, mycophenolate mofetil, cyclophosphamide (Level of Evidence C) 2
• Collaborate with pulmonologist/rheumatologist for immune-modulating therapy 2

3. Iron Overload Cardiomyopathy 3

• Iron chelation therapy when indicated

4. AL Amyloidosis 2

• Chemotherapy directed at plasma cell dyscrasia
• Median survival only 4 months once heart failure develops, emphasizing urgency of diagnosis 2

Supportive Heart Failure Management

For All RCM Patients 4, 9

• Diuretics: Essential for managing elevated filling pressures and congestion
• Rate control for atrial fibrillation: Beta-blockers, verapamil, or diltiazem 9
• Anticoagulation: Mandatory for any atrial fibrillation (even subclinical >24 hours), independent of CHA₂DS₂-VASc score; use direct oral anticoagulants first-line 9
• Critical consideration: Anticoagulation should be strongly considered even without AF due to high thrombotic risk, particularly in sarcomeric RCM 7, 10

If Systolic Dysfunction Develops (EF <50%) 9

• Initiate guideline-directed medical therapy for heart failure with reduced ejection fraction
• Evaluate for concomitant causes (coronary disease, valvular disease)

Device Therapy

ICD Implantation 2, 4

• Reasonable for cardiac sarcoidosis patients (Level of Evidence C) 2
• Consider in high-risk patients with multiple sudden death risk factors
• Program antitachycardia pacing to minimize shocks 9

Advanced Therapies

Cardiac Transplantation 2, 4

• Refer for evaluation when:
  • Advanced heart failure (NYHA class III-IV) despite optimal medical therapy
  • Life-threatening refractory ventricular arrhythmias
  • For sarcoidosis: absence of significant extracardiac disease burden (Level of Evidence C) 2
• Important: Sarcoidosis can recur in transplanted heart but usually responds to steroids 2
• Perform cardiopulmonary exercise testing to quantify functional limitation and aid selection 9

Critical Pitfalls to Avoid

1. Never interpret 99mTc-PYP scan without first excluding monoclonal light chains - AL amyloidosis can show positive uptake 1

2. Do not rely on endomyocardial biopsy alone for sarcoidosis - patchy distribution means negative biopsy doesn't exclude disease 2

3. Recognize that RCM may be a stage in disease evolution - some conditions present initially as hypertrophic cardiomyopathy before developing restrictive physiology 5

4. Anticoagulate liberally - thrombotic events are common, especially in sarcomeric variants, even without documented atrial fibrillation 7, 10

5. Pediatric RCM with sarcomeric variants has particularly poor prognosis - more aggressive monitoring and earlier transplant evaluation warranted 10